长春高新股价微跌0.15% 子公司双抗ADC药物获批临床

Core Viewpoint - Changchun High-tech's stock price is experiencing a slight decline, reflecting market fluctuations and investor sentiment in the biopharmaceutical sector [1] Company Overview - Changchun High-tech operates in the biopharmaceutical industry, focusing on the production and sales of biological drugs and traditional Chinese medicine [1] - The company's core subsidiary, Jinsai Pharmaceutical, specializes in the research and development of genetically engineered biological drugs, including a series of growth hormone products [1] Recent Developments - Jinsai Pharmaceutical's application for clinical trials of the self-developed injection GenSci143 has been accepted by the National Medical Products Administration [1] - GenSci143 is a bispecific antibody-drug conjugate targeting B7-H3 and PSMA, which has potential dual therapeutic effects in targeted chemotherapy and tumor immunotherapy [1] Financial Performance - On the trading day, Changchun High-tech's stock price was reported at 103.33 yuan, with a maximum of 103.99 yuan and a minimum of 102.90 yuan, and a trading volume of 574 million yuan [1] - The company experienced a net outflow of 55.31 million yuan in principal funds on that day, with a cumulative net outflow of 107 million yuan over the past five days [1]